Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

JAMA Oncol. 2019 Jul 1;5(7):1060-1062. doi: 10.1001/jamaoncol.2019.0869.

Abstract

This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androstenes / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Biomarkers, Tumor / genetics
  • Humans
  • Male
  • Nitriles
  • Phenylthiohydantoin / analogs & derivatives*
  • Phenylthiohydantoin / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / genetics
  • Protein Isoforms / genetics
  • Receptors, Androgen / genetics*
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics

Substances

  • AR protein, human
  • Androstenes
  • Antineoplastic Agents
  • Benzamides
  • Biomarkers, Tumor
  • Nitriles
  • Protein Isoforms
  • Receptors, Androgen
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Phenylthiohydantoin
  • enzalutamide
  • abiraterone